HEART TRANSPLANTATION

HEART TRANSPLANTATION
Overall ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

NUMBER OF HEART TRANSPLANTS REPORTED BY YEAR
This figure includes only the heart transplants that are reported to the ISHLT Transplant Registry. As such, the presented data may not mirror the changes in the number of heart transplants performed worldwide. NOTE: This figure includes only the heart transplants that are reported to the ISHLT Transplant Registry. As such, the presented data may not mirror the changes in the number of heart transplants performed worldwide ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

AVERAGE CENTER VOLUME Heart Transplants: January 1, 2003 – June 30, 2010
ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

HEART TRANSPLANTS: Donor Age by Year of Transplant

AGE DISTRIBUTION OF HEART TRANSPLANT RECIPIENTS BY ERA
The age distribution of heart transplant recipients was compared between the eras using a chi-square test. A significant p-value means that at least one of the groups is different than the others but it doesn’t identify which group it is. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

HEART TRANSPLANTATION Kaplan-Meier Survival (1/1982-6/2005)
Survival was calculated using the Kaplan-Meier method, which incorporates information from all transplants for whom any follow-up has been provided. Since many patients are still alive and some patients have been lost to follow-up, the survival rates are estimates rather than exact rates because the time of death is not known for all patients. Therefore, 95% confidence limits are provided about the survival rate estimate; the survival rate shown is the best estimate but the true rate will most likely fall within these limits. The half-life is the estimated time point at which 50% of all of the recipients have died. The conditional half-life is the estimated time point at which 50% of the recipients who survive to at least 1 year have died. Because the decline in survival is greatest during the first year following transplantation, the conditional survival provides a more realistic expectation of survival time for recipients who survive the early post-transplant period. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

HEART TRANSPLANTATION
Adult Recipients ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

DIAGNOSIS IN ADULT HEART TRANSPLANTS

DIAGNOSIS IN ADULT HEART TRANSPLANTS Cardiomyopathy vs. CAD by Location

ADULT HEART TRANSPLANTS: DIAGNOSIS BY LOCATION Transplants between January 2005 and June 2010

ADULT HEART TRANSPLANTATION Donor and Recipient Characteristics
(N=39,812 ) 2002-6/2010 (N=27,387) p-value Recipient age (years) 54.0 ± 11.0 ( ) 54.0 ± 12.4 ( ) 0.5756 Donor age (years) 31.0 ± 12.8 ( ) 34.0 ± 13.1 ( ) <0.0001 Recipient/donor gender (% male) 80.5%/ 68.4% 77.2%/ 69.5% <0.0001/ Recipient weight (kg) 75.0 ± 16.7 ( ) 78.0 ± 17.2 ( ) Recipient height (cm) 173.0 ± 11.3 ( ) 175.0 ± 10.7 ( ) Recipient BMI 25.0 ± 4.3 ( ) 25.8 ± 4.7 ( ) Donor weight (kg) 75.0 ± 17.6 ( )* 78.0 ± 17.1 ( ) Donor height (cm) 175.0 ± 18.9 ( )* 175.0 ± 10.3 ( ) Donor BMI 24.2 ± 4.5 ( )* 25.2 ± 4.9 ( ) Recipient/donor diabetes mellitus 14.5%*/ 1.6%* 22.7%/ 2.5% <0.0001/ <0.0001 Recipient amiodarone use (US only) 22.6%* 29.4% Recipient/donor cigarette history -/ 37.5%* 46.9%**/ 23.6% -/ <0.0001 Recipient/donor hypertension 34.6%*/ 10.8%* 40.9%/ 12.4% Recipient prior cardiac surgery - 43.0%** Comparisons for categorical variables were made using the chi-square statistic. Multiple groups were compared using single p-value. A significant p-value in these cases means that at least one of the groups is different than the others but it doesn’t identify which group it is. Comparisons for continuous variables were made using Wilcoxon–Mann–Whitney test. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT Continuous factors are expressed as median ± standard deviation (5th-95th percentiles) 2011 * Based on 4/ transplants. ** Based on 7/2004-6/2010 transplants.

(N=39,812 ) 2002-6/2010 (N=27,387) p-value Recipient Peripheral Vascular Disease 3.9%* 3.0% <0.0001 Recipient previous malignancy 3.5%* 5.3% Recipient COPD 3.2%* 3.6% 0.0601 Ischemic time (hours) 2.6 ± 1.5 ( ) 3.0 ± 1.5 ( ) Most recent PRA > 10% Overall 7.8% 9.2%** 0.0016 Class I 13.3%*** Class II 9.0%*** Creatinine at time of transplant 1.2 ± 9.7 ( ) 1.2 ± 0.9 ( ) 0.0001 Pulmonary vascular resistance (Wood units) 2.1 ± 2.2 ( )* 2.1 ± 2.0 ( ) Comparisons for categorical variables were made using the chi-square statistic. Multiple groups were compared using single p-value. A significant p-value in these cases means that at least one of the groups is different than the others but it doesn’t identify which group it is. Comparisons for continuous variables were made using Wilcoxon–Mann–Whitney test. Continuous factors are expressed as median ± standard deviation (5th-95th percentiles) * Based on 4/ transplants. ** Based on US /2004 transplants and non US /2010 transplants *** Based on US 7/2004-6/2010 transplants. Until mid-2004 PRA was collected in US as a single percentage. After this date, PRA was collected separately for Class I and Class II. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT (Cont’d) 2011

(N=39,812 ) 2002-6/2010 (N=27,387) p-value HLA Mismatches 0.0003 0-2 4.8% 4.2% 3-4 41.6% 40.4% 5-6 53.6% 55.4% Diagnosis <0.0001 Coronary artery disease 45.7% 39.5% Cardiomyopathy 46.4% 51.6% Valvular 3.7% 3.0% Retransplant 1.9% 2.4% Congenital 2.8% Other causes 0.4% 0.7% ISHLT ISHLT J Heart Lung Transplant Oct; 30 (10): (Cont’d) 2011

(N=39,812 ) 2002-6/2010 (N=27,387) p-value Donor cause of death <0.0001 Head trauma 45.7% 50.2% Stroke 28.5% 28.8% Other 25.8% 21.1% Pre-operative support (multiple items may be reported) Hospitalized at time of transplant 58.7% 46.0% On IV inotropes 55.3%* 44.8% LVAD 1.7%*** 19.0% IABP 6.7% 0.7815 RVAD - 4.1%**** Ventilator 3.5% 3.0% 0.0065 TAH 0.1%*** 0.5% ECMO 0.3%** 0.8% * Based on 4/ transplants. ** Based on 5/ transplants. *** Based on 11/ transplants. **** Based on /2010 transplants. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT (Cont’d) 2011

ADULT HEART TRANSPLANTATION PRA DISTRIBUTION Transplants between July 2004 and June 2010
Only known PRA values are included in the tabulation. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT If Class I and Class II values were reported separately Class I PRA value was used 2011

ADULT HEART TRANSPLANTATION % OF PATIENTS BRIDGED WITH MECHANICAL CIRCULATORY SUPPORT* (Transplants: 1/2000 – 12/2009) ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT * LVAD, RVAD, TAH 2011

ADULT HEART TRANSPLANTATION % OF PATIENTS BRIDGED WITH RVAD
ADULT HEART TRANSPLANTATION % OF PATIENTS BRIDGED WITH RVAD* (Transplants: 1/2005 – 12/2009) ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT * RVAD, RVAD+LVAD 2011

ADULT HEART TRANSPLANTATION Number of Combined Organ Transplants Reported By Year and Type of Transplant Transplants with unknown donor age were excluded from this tabulation. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

ADULT HEART TRANSPLANTS DONOR AGE DISTRIBUTION BY LOCATION Transplants between January 2000 and June 2010 Transplants with unknown donor age were excluded from this tabulation. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT Mean/median donor age: Europe = 38.3/40.0 North America = 31.7/29.0 Other = 32.9/31.0 2011

ADULT HEART TRANSPLANTS RECIPIENT AGE DISTRIBUTION BY LOCATION Transplants between January 2000 and June 2010 ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT Mean/median recipient age: Europe = 50.1/53.0 North America = 51.8/55.0 Other = 48.3/51.0 2011

ADULT HEART TRANSPLANTS RECIPIENT BMI DISTRIBUTION BY LOCATION Transplants between January 2000 and June 2010 ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

ADULT HEART TRANSPLANTS RECIPIENT DIABETES MELLITUS BY LOCATION Transplants between January 2000 and June 2010 ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

ADULT HEART TRANSPLANTS RECIPIENT CIGARETTE HISTORY BY LOCATION Transplants between July 2004 and June 2010 ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Era (Transplants: 1/1982 – 6/2009)
Survival was calculated using the Kaplan-Meier method, which incorporates information from all transplants for whom any follow-up has been provided. Since many patients are still alive and some patients have been lost to follow-up, the survival rates are estimates rather than exact rates because the time of death is not known for all patients. The half-life is the estimated time point at which 50% of all of the recipients have died. Survival rates were compared using the log-rank test statistic. No adjustments were made for multiple comparisons. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

ADULT HEART TRANSPLANTATION Conditional Kaplan-Meier Survival by Era (Transplants: 1/1982 – 6/2009)
Survival was calculated using the Kaplan-Meier method, which incorporates information from all transplants for whom any follow-up has been provided. Since many patients are still alive and some patients have been lost to follow-up, the survival rates are estimates rather than exact rates because the time of death is not known for all patients. Conditional survival is shown in this figure; this is the survival following 1 year for all patients who survived to 1 year. The conditional half-life is the estimated time point at which 50% of the recipients who survive to at least 1 year have died. Survival rates were compared using the log-rank test statistic. No adjustments were made for multiple comparisons. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Age Group (Transplants: 1/1982-6/2009)

ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Age Group (Transplants: 1/2002-6/2009)
Survival was calculated using the Kaplan-Meier method, which incorporates information from all transplants for whom any follow-up has been provided. Since many patients are still alive and some patients have been lost to follow-up, the survival rates are estimates rather than exact rates because the time of death is not known for all patients. Survival rates were compared using the log-rank test statistic. No adjustments were made for multiple comparisons. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Diagnosis (Transplants: 1/1982-6/2009)

ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Diagnosis Conditional on Survival to 1 Year (Transplants: 1/1982-6/2009) Survival was calculated using the Kaplan-Meier method, which incorporates information from all transplants for whom any follow-up has been provided. Since many patients are still alive and some patients have been lost to follow-up, the survival rates are estimates rather than exact rates because the time of death is not known for all patients. The half-life is the estimated time point at which 50% of all of the recipients have died. Survival rates were compared using the log-rank test statistic. No adjustments were made for multiple comparisons. Conditional survival was performed by limiting the group of patients analyzed to those who have survived to at least 1 year. Thus it is possible to examine longer term survival after excluding early deaths. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Era (Transplants: 1/1982 – 6/2009) Diagnosis: Cardiomyopathy Survival was calculated using the Kaplan-Meier method, which incorporates information from all transplants for whom any follow-up has been provided. Since many patients are still alive and some patients have been lost to follow-up, the survival rates are estimates rather than exact rates because the time of death is not known for all patients. The half-life is the estimated time point at which 50% of all of the recipients have died. Survival rates were compared using the log-rank test statistic. No adjustments were made for multiple comparisons. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Era (Transplants: 1/1982 – 6/2009) Diagnosis: Coronary Artery Disease Survival was calculated using the Kaplan-Meier method, which incorporates information from all transplants for whom any follow-up has been provided. Since many patients are still alive and some patients have been lost to follow-up, the survival rates are estimates rather than exact rates because the time of death is not known for all patients. The half-life is the estimated time point at which 50% of all of the recipients have died. Survival rates were compared using the log-rank test statistic. No adjustments were made for multiple comparisons. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Era (Transplants: 1/1982 – 6/2009) Diagnosis: Congenital Survival was calculated using the Kaplan-Meier method, which incorporates information from all transplants for whom any follow-up has been provided. Since many patients are still alive and some patients have been lost to follow-up, the survival rates are estimates rather than exact rates because the time of death is not known for all patients. The half-life is the estimated time point at which 50% of all of the recipients have died. Survival rates were compared using the log-rank test statistic. No adjustments were made for multiple comparisons. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Era (Transplants: 1/1982 – 6/2009) Diagnosis: Retransplant Survival was calculated using the Kaplan-Meier method, which incorporates information from all transplants for whom any follow-up has been provided. Since many patients are still alive and some patients have been lost to follow-up, the survival rates are estimates rather than exact rates because the time of death is not known for all patients. The half-life is the estimated time point at which 50% of all of the recipients have died. Survival rates were compared using the log-rank test statistic. No adjustments were made for multiple comparisons. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Era (Transplants: 1/1982 – 6/2009) Diagnosis: Valvular Survival was calculated using the Kaplan-Meier method, which incorporates information from all transplants for whom any follow-up has been provided. Since many patients are still alive and some patients have been lost to follow-up, the survival rates are estimates rather than exact rates because the time of death is not known for all patients. The half-life is the estimated time point at which 50% of all of the recipients have died. Survival rates were compared using the log-rank test statistic. No adjustments were made for multiple comparisons. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Diagnosis (Transplants: 1/2002-6/2009)

ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Diagnosis Conditional on Survival to 1 Year (Transplants: 1/2002-6/2009) Survival was calculated using the Kaplan-Meier method, which incorporates information from all transplants for whom any follow-up has been provided. Since many patients are still alive and some patients have been lost to follow-up, the survival rates are estimates rather than exact rates because the time of death is not known for all patients. Survival rates were compared using the log-rank test statistic. No adjustments were made for multiple comparisons. Conditional survival was performed by limiting the group of patients analyzed to those who have survived to at least 1 year. Thus it is possible to examine longer term survival after excluding early deaths. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by PVR (Transplants: 1/2002-6/2009)

ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Donor/Recipient Weight Ratio (Transplants: 1/2002-6/2009) For Recipients with PVR: 1- < 3 Wood units Survival was calculated using the Kaplan-Meier method, which incorporates information from all transplants for whom any follow-up has been provided. Since many patients are still alive and some patients have been lost to follow-up, the survival rates are estimates rather than exact rates because the time of death is not known for all patients. Survival rates were compared using the log-rank test statistic. No adjustments were made for multiple comparisons. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Donor/Recipient Weight Ratio (Transplants: 1/2002-6/2009) For Recipients with PVR: 3- < 5 Wood units Survival was calculated using the Kaplan-Meier method, which incorporates information from all transplants for whom any follow-up has been provided. Since many patients are still alive and some patients have been lost to follow-up, the survival rates are estimates rather than exact rates because the time of death is not known for all patients. Survival rates were compared using the log-rank test statistic. No adjustments were made for multiple comparisons. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Donor/Recipient Weight Ratio (Transplants: 1/2002-6/2009) For Recipients with PVR: 5+ Wood units Survival was calculated using the Kaplan-Meier method, which incorporates information from all transplants for whom any follow-up has been provided. Since many patients are still alive and some patients have been lost to follow-up, the survival rates are estimates rather than exact rates because the time of death is not known for all patients. Survival rates were compared using the log-rank test statistic. No adjustments were made for multiple comparisons. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by VAD usage (Transplants: 4/1994-6/2009)
Survival was calculated using the Kaplan-Meier method, which incorporates information from all transplants for whom any follow-up has been provided. Since many patients are still alive and some patients have been lost to follow-up, the survival rates are estimates rather than exact rates because the time of death is not known for all patients. Survival rates were compared using the log-rank test statistic. No adjustments were made for multiple comparisons. Only pair-wise comparisons statistically significant at p ≤ 0.05 are shown on the slide. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by VAD usage (Transplants: 1/1999-6/2009) Conditional on Survival to 6 Months Survival was calculated using the Kaplan-Meier method, which incorporates information from all transplants for whom any follow-up has been provided. Since many patients are still alive and some patients have been lost to follow-up, the survival rates are estimates rather than exact rates because the time of death is not known for all patients. Conditional survival is shown in this figure; this is the survival following 6 months for all patients who survived to 6 months. Survival rates were compared using the log-rank test statistic. No adjustments were made for multiple comparisons. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

ADULT HEART RE-TRANSPLANTS 1-Year Survival
Survival was computed using the Kaplan-Meier method. Rates were compared using the log-rank test statistic. Rates are shown only for groups with 10 or more patients at risk (alive with follow-up) at 1 year. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

ADULT HEART RECIPIENTS Cross-Sectional Analysis Functional Status of Surviving Recipients (Follow-ups: June 2010) This figure shows the functional status reported on the 1-year, 3-year and 5-year annual follow-ups. Because all follow-ups between 1995 and June 2010 were included, the bars do not include the same patients. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

ADULT HEART RECIPIENTS Functional Status of Surviving Recipients US Recipients Only (Follow-ups: March June 2010) From March 2005 functional status in US is collected using Karnofsky score for adult recipients and Lansky score for pediatric recipients. This figure shows the functional status reported on the 1-year, 2-year and 3-year annual follow-ups. Because all follow-ups between March 2005 and June 2010 were included, the bars do not include the same patients. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

ADULT HEART RECIPIENTS Employment Status of Surviving Recipients (Follow-ups: 1995 - June 2010)
This figure shows the employment status reported on annual follow-ups. Because all follow-ups between 1995 and June 2010 were included, the bars do not include the same patients. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

ADULT HEART RECIPIENTS Employment Status of Surviving Recipients Age at Follow-up: Years (Follow-ups: June 2010) This figure shows the employment status reported on annual follow-ups. Because all follow-ups between 1995 and June 2010 were included, the bars do not include the same patients. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

ADULT HEART RECIPIENTS Rehospitalization Post-transplant of Surviving Recipients (Follow-ups: June 2010) This figure shows the hospitalizations reported on the annual follow-ups, representing the hospitalizations between discharge and 1 year, between the 2-year and 3-year follow-up, and between the 4-year and 5-year follow-ups, respectively. Because all follow-ups between 1995 and June 2010 were included, the bars do not include the same patients. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

ADULT HEART RECIPIENTS Induction Immunosuppression (Transplants: January 2002 – June 2010)
ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT Analysis is limited to patients who were alive at the time of the discharge 2011

ADULT HEART RECIPIENTS Induction Immunosuppression by Location Transplants: January 2002 – June 2010
ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT Analysis is limited to patients who were alive at the time of the discharge 2011

ADULT HEART RECIPIENTS Induction Immunosuppression (Transplants: 1997, 2002 and 1/2010-6/2010)
Note: 3.3% of transplant recipients in 1/2010-6/2010 received Alemtuzumab ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 Analysis is limited to patients who were alive at the time of the discharge

ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Induction Type (Transplants: 1/2000-6/2009, conditional on survival to 14 days) Survival was calculated using the Kaplan-Meier method, which incorporates information from all transplants for whom any follow-up has been provided. Since many patients are still alive and some patients have been lost to follow-up, the survival rates are estimates rather than exact rates because the time of death is not known for all patients. Survival rates were compared using the log-rank test statistic. No adjustments were made for multiple comparisons. Only pair-wise comparisons statistically significant at p ≤ 0.05 are shown on the slide. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

ADULT HEART RECIPIENTS Maintenance Immunosuppression at Time of Follow-up (Follow-ups: January June 2010) This figure shows the maintenance immunosuppression reported as being provided at the time of the 1-year and 5-year annual follow-up forms. To provide a snapshot of current practice, only follow-ups occurring between January 2007 and June 2010 were included. Therefore, this figure does not represent changes in practice between the 1-year follow-up and 5-year follow-up on a cohort of patients. The patients in the 1-year tabulation are not the same patients as in the 5-year tabulation. NOTE: Different patients are analyzed in Year 1 and Year 5 ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 Analysis is limited to patients who were alive at the time of the follow-up

ADULT HEART RECIPIENTS Maintenance Immunosuppression at Time of Follow-up For the Same Patients (Follow-ups: January June 2010) This figure shows the maintenance immunosuppression reported as being provided at the time of the 1-year and 5-year annual follow-up forms. To provide a snapshot of current practice, only follow-ups occurring between January 2000 and June 2010 were included. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 Analysis is limited to patients who were alive at the time of the follow-up

ADULT HEART RECIPIENTS Maintenance Immunosuppression at Time of 1 Year Follow-up
This figure shows the maintenance immunosuppression reported as being provided at the time of the 1-year annual follow-up forms. As different patients were transplanted each year this figure does not represent changes in immunosuppression for individual patients but may represent changes in practice. NOTE: Different patients are analyzed in each time frame. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 Analysis is limited to patients who were alive at the time of the follow-up

ADULT HEART RECIPIENTS Maintenance Immunosuppression Drug Combinations at Time of Follow-up For the Same Patients (Follow-ups: January June 2010) This figure shows the maintenance immunosuppression reported as being provided at the time of the 1-year and 5-year annual follow-up forms for the same patients based on follow-ups occurring between January 2000 and June 2010. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT Analysis is limited to patients who were alive at the time of the follow-up 2011

ADULT HEART RECIPIENTS Maintenance Immunosuppression Drug Combinations at Time of Follow-up (Follow-ups: January June 2010) This figure shows the maintenance immunosuppression reported as being provided at the time of the 1-year and 5-year annual follow-up forms. To provide a snapshot of current practice, only follow-ups occurring between January 2005 and June 2010 were included. Therefore, this figure does not represent changes in practice between the 1-year follow-up and 5-year follow-up on a cohort of patients. The patients in the 1-year tabulation are not the same patients as in the 5-year tabulation. NOTES: Different patients are analyzed in Year 1 and Year 5. In the Year 1 cohort 88.8% of patients were on prednisone; in the Year 5 cohort 54.0% of patients were on prednisone. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 Analysis is limited to patients who were alive at the time of the follow-up

ADULT HEART RECIPIENTS Maintenance Immunosuppression Drug Combinations at Time of Follow-up by Location (Follow-ups: January June 2010) This figure shows the maintenance immunosuppression reported as being provided at the time of the 1-year and 5-year annual follow-up forms. To provide a snapshot of current practice, only follow-ups occurring between January 2005 and June 2010 were included. Therefore, this figure does not represent changes in practice between the 1-year follow-up and 5-year follow-up on a cohort of patients. The patients in the 1-year tabulation are not the same patients as in the 5-year tabulation. Year 1 Year 5 ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT NOTES: Different patients are analyzed in Year 1 and Year 5. 2011 Analysis is limited to patients who were alive at the time of the follow-up

PERCENTAGE OF ADULT HEART TRANSPLANT RECIPIENTS Experiencing Rejection between Transplant Discharge and 1-Year Follow-Up Stratified by Type of Induction (Follow-ups: July 1, June 30, 2010) Overall 18-44 45-62 63+ Female Male Because of a modification in the data collection, the analysis is limited to follow-ups occurring on or after July 2004. Comparisons were made using the chi-square statistic. No adjustments were made for multiple comparisons. Only pair-wise comparisons statistically significant at p ≤ 0.05 are shown on the slide. All groups: all no induct vs. poly and no induct vs. IL-2R comparisons are significant at p < 0.05 except 45-62: no induct vs. poly and M: no induct vs. poly Overall: no induct vs. OKT3 (p=0.0120); poly vs. IL-2R (p=0.0019) 45-62: poly vs. IL-2R (p=0.0280) 63+: no induct vs. OKT3 (p=0.0093) M: poly vs. IL-2R (p=0.0014) Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti-rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents. Analysis is limited to patients who were alive at the time of the follow-up ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT No induction: N=4,744 Polyclonal: N=1,956 IL-2R antagonist: N=2,779 OKT3: N=187 2011

PERCENTAGE OF ADULT HEART TRANSPLANT RECIPIENTS Experiencing Rejection between Transplant Discharge and 1-Year Follow-Up Stratified by Maintenance Immunosuppression (Follow-ups: July 1, June 30, 2010) Comparisons were made using the chi-square statistic. No adjustments were made for multiple comparisons. 18-44 45-62 63+ Male Female Overall Overall: p < 18-44: p < 45-62: p < 63+: p = Female: p < Male: p < Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti-rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents. Analysis is limited to patients who were alive at the time of the follow-up Cyclosporine + MMF/MPA: N = 3,113 Tacrolimus + MMF/MPA: N = 5,365 ISHLT ISHLT J Heart Lung Transplant Oct; 30 (10): 2011 NOTE: There were 163 patients with cyclosporine + AZA and 57 with tacrolimus+AZA. These groups were excluded due to small numbers.

ADULT HEART TRANSPLANTATION Kaplan-Meier Survival Stratified by Treatment for Rejection Within 1st Year Conditional on survival to 1 year (1 Year follow-ups: 7/2004-6/2009) Because of a modification in the data collection, the analysis is limited to follow-ups occurring on or after July 2004. Survival was calculated using the Kaplan-Meier method, which incorporates information from all transplants for whom any follow-up has been provided. Since many patients are still alive and some patients have been lost to follow-up, the survival rates are estimates rather than exact rates because the time of death is not known for all patients. Survival rates were compared using the log-rank test statistic. Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti-rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

FREEDOM FROM HOSPITALIZATION FOR REJECTION BY ERA For Adult Heart Recipients (Transplants: April 1994-June 2009) Freedom from hospitalization for rejection rates by era were computed using the Kaplan-Meier method. The development of severe renal dysfunction is reported on annual follow-ups; a date of diagnosis is not provided. For this figure the midpoint between the date of previous follow-up (when event had not occurred) and the date of follow-up when the event was reported was used as the date of occurrence. Patients were included in the analysis until an unknown response for the outcome of interest was reported. Therefore, the rates seen here may differ from those reported in the cumulative prevalence slide which is based on only those patients with known responses for each of the outcomes at all follow-up time points. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

Total N with known response
POST-HEART TRANSPLANT MORBIDITY FOR ADULTS Cumulative Prevalence in Survivors at 1, 5 and 10 Years Post-Transplant (Follow-ups: April June 2010) Outcome Within 1 Year Total N with known response Within 5 Years Within 10 Years Hypertension* 72.9% (N = 25,435) 92.9% (N = 11,156) - Renal Dysfunction 26.6% (N = 26,918) 30.3% (N = 13,239) 36.0% (N = 4,274) Abnormal Creatinine < 2.5 mg/dl 18.1% 20.5% 24.4% Creatinine > 2.5 mg/dl 6.7% 7.0% 5.3% Chronic Dialysis 1.5% 2.3% 4.8% Renal Transplant 0.3% 0.4% Hyperlipidemia* 58.2% (N = 26,773) 87.9% (N = 12,483) Diabetes* 26.9% (N = 26,913) 37.4% (N = 12,195) Cardiac Allograft Vasculopathy 7.8% (N = 24,361) 30.6% (N = 8,988) 51.1% (N = 2,137) This table shows the percentage of patients experiencing various morbidities as reported within 1, 5 and 10 years following transplantation. The percentages are based on patients with known responses. To reduce bias, only patients with responses reported on every follow-up through the 5-year annual (or 10-year annual) follow-up were included in the 5-year (or 10-year) analysis. Because the outcomes are reported to be unknown at different rates the number with known responses for each outcome are also provided. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT * Data are not available 10 years post transplant 2011

POST-HEART TRANSPLANT MORBIDITY FOR ADULTS Cumulative Prevalence in Survivors at 1, 5 and 10 Years Post-Transplant (Transplants: June 2000) For the Same Patients Outcome Within 1 Year Total N with known response Within 5 Years Within 10 Years Renal Dysfunction 18.7% (N = 1,852) 26.9% 34.0% Abnormal Creatinine < 2.5 mg/dl 12.6% 21.2% 25.0% Creatinine > 2.5 mg/dl 5.9% 4.6% 4.0% Chronic Dialysis 0.1% 0.7% 3.5% Renal Transplant 0.2% 0.4% 1.5% Cardiac Allograft Vasculopathy 7.2% 30.2% 50.9% This table shows the percentage of patients experiencing various morbidities as reported within 1, 5 and 10 years following transplantation. The percentages are based on patients with known responses. To reduce bias, only patients with responses reported on every follow-up through the 5-year annual (or 10-year annual) follow-up were included in the 5-year (or 10-year) analysis. Because the outcomes are reported to be unknown at different rates the number with known responses for each outcome are also provided. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

POST-HEART TRANSPLANT MORBIDITY FOR ADULTS Cumulative Prevalence in Survivors within 1 and 5 Years Post-Transplant (Transplants: June 2005) For the Same Patients Outcome Within 1 Year Total N with known response Within 5 Years Hypertension 75.1% (N = 3,273) 89.5% Renal Dysfunction 26.3% 28.9% Abnormal Creatinine < 2.5 mg/dl 20.7% 22.1% Creatinine > 2.5 mg/dl 4.8% 5.0% Chronic Dialysis 0.5% 1.5% Renal Transplant 0.3% Hyperlipidemia 73.4% 90.7% Diabetes 28.0% 40.0% Cardiac Allograft Vasculopathy 5.4% 27.1% This table shows the percentage of patients experiencing various morbidities as reported within 1 and 5 years following transplantation. The percentages are based on patients with known responses. To reduce bias, only patients with responses reported on every follow-up through the 5-year annual follow-up were included in the 5-year analysis. Because the outcomes are reported to be unknown at different rates the number with known responses for each outcome are also provided. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

FREEDOM FROM CARDIAC ALLOGRAFT VASCULOPATHY For Adult Heart Recipients (Transplants: April 1994-June 2009) Freedom from CAV rates by era were computed using the Kaplan-Meier method. The development of CAV is reported on annual follow-ups; a date of diagnosis is not provided. For this figure the midpoint between the date of previous follow-up (when event had not occurred) and the date of follow-up when the event was reported was used as the date of occurrence. Patients were included in the analysis until an unknown response for the outcome of interest was reported. Therefore, the rates seen here may differ from those reported in the cumulative prevalence slide which is based on only those patients with known responses for each of the outcomes at all follow-up time points. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

FREEDOM FROM SEVERE RENAL DYSFUNCTION BY ERA
FREEDOM FROM SEVERE RENAL DYSFUNCTION BY ERA* For Adult Heart Recipients (Transplants: April 1994-June 2009) Freedom from severe renal dysfunction rates by era were computed using the Kaplan-Meier method. The development of severe renal dysfunction is reported on annual follow-ups; a date of diagnosis is not provided. For this figure the midpoint between the date of previous follow-up (when event had not occurred) and the date of follow-up when the event was reported was used as the date of occurrence. Patients were included in the analysis until an unknown response for the outcome of interest was reported. Therefore, the rates seen here may differ from those reported in the cumulative prevalence slide which is based on only those patients with known responses for each of the outcomes at all follow-up time points. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

PATIENT SURVIVAL AFTER REPORT OF CAV WITHIN 3 YEARS OF TRANSPLANT AND PATIENT SURVIVAL IN PATIENTS WITHOUT CAV* (Transplants: April 1994-June 2009) Survival following CAV and survival from the median time to CAV development were computed using the Kaplan-Meier method. The development of CAV is reported on annual follow-ups; a date of diagnosis is not provided. For this figure the midpoint between the date of previous follow-up (when event had not occurred) and the date of follow-up when the event was reported was used as the date of occurrence. * Survival for patients without CAV within 3 years after transplant was conditioned on survival to median time of CAV development (509 days). Median time to CAV development is based on patients who developed CAV within 3 years of transplant. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

PATIENT SURVIVAL AFTER REPORT OF CAV WITHIN 3 YEARS OF TRANSPLANT AND PATIENT SURVIVAL IN PATIENTS WITHOUT CAV* BY ERA (Transplants: April 1994-June 2009) Survival following CAV and survival from the median time to CAV development by era were computed using the Kaplan-Meier method. No adjustments were made for multiple comparisons. The development of CAV is reported on annual follow-ups; a date of diagnosis is not provided. For this figure the midpoint between the date of previous follow-up (when event had not occurred) and the date of follow-up when the event was reported was used as the date of occurrence. * Survival for patients without CAV within 3 years after transplant was conditioned on survival to median time of CAV development (509 days). Median time to CAV development is based on patients who developed CAV within 3 years of transplant. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

MALIGNANCY POST-HEART TRANSPLANTATION FOR ADULTS Cumulative Prevalence in Survivors (Follow-ups: April June 2010) Malignancy/Type 1-Year Survivors 5-Year Survivors 10-Year Survivors No Malignancy 27,316 (97.3%) 11,751 (85.9%) 3,122 (71.3%) Malignancy (all types combined) 764 (2.7%) 1,933 (14.1%) 1,256 (28.7%) Malignancy Type Skin 373 1,293 896 Lymph 161 154 87 Other 177 548 393 Type Not Reported 53 37 12 ”Other” includes: prostate (11, 35, 21), adenocarcinoma (7, 7, 4), lung (6, 4, 1), bladder (4, 5, 4), Kaposi's sarcoma (0, 3, 1), breast (2, 7, 2), cervical (2, 5, 2), colon (2, 4, 2), and renal (2, 7, 2). Numbers in parentheses are those reported within 1 year, 5 years and 10 years, respectively. This table shows the percentage of patients with malignancies reported within 1, 5 and 10 years following transplantation. The percentages are based on patients with known responses. To reduce bias, only patients with responses reported on every follow-up through the 5-year annual follow-up were included in the “5-Year Survivors” column. Similarly, only patients with responses reported on every follow-up through the 10-year annual follow-up were included in the “10-Year Survivors” column. NOTE: Multiple types may be reported; sum of types may be greater than total number with malignancy. ISHLT ISHLT J Heart Lung Transplant Oct; 30 (10): 2011

FREEDOM FROM MALIGNANCY For Adult Heart Recipients (Follow-ups: April 1994 - June 2010)
Freedom from malignancy rates were computed using the Kaplan-Meier method. The development of malignancy is reported on annual follow-ups; a date of diagnosis is not provided. For this figure the midpoint between the date of previous follow-up (when malignancy had not been reported) and the date of follow-up when the malignancy was reported was used as the date of occurrence. Patients were included in the analysis until an unknown response for malignancy was reported. Therefore, the rates seen here may differ from those reported in the cumulative prevalence slide which is based on only those patients with known responses for malignancy at all follow-up time points. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

FREEDOM FROM MALIGNANCY by Maintenance Immunosuppression Combinations at Discharge For Adult Heart Recipients (Transplants: January June 2009) Conditional on Survival to 14 days Freedom from malignancy rates were computed using the Kaplan-Meier method. The development of malignancy is reported on annual follow-ups; a date of diagnosis is not provided. For this figure the midpoint between the date of previous follow-up (when malignancy had not been reported) and the date of follow-up when the malignancy was reported was used as the date of occurrence. Patients were included in the analysis until an unknown response for malignancy was reported. Therefore, the rates seen here may differ from those reported in the cumulative prevalence slide which is based on only those patients with known responses for malignancy at all follow-up time points. Freedom from malignancy rates were compared using the log-rank test statistic. A significant p-value means that at least one of the groups is different than the others but it doesn’t identify which group it is. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

FREEDOM FROM MALIGNANCY For Adult Heart Recipients (Transplants : April 1994 - June 2009)

FREEDOM FROM SKIN MALIGNANCY For Adult Heart Recipients (Transplants : April 1994 - June 2009)

FREEDOM FROM SKIN MALIGNANCY by Location For Adult Heart Recipients (Follow-ups: April June 2010) Freedom from malignancy rates were computed using the Kaplan-Meier method. The development of malignancy is reported on annual follow-ups; a date of diagnosis is not provided. For this figure the midpoint between the date of previous follow-up (when malignancy had not been reported) and the date of follow-up when the malignancy was reported was used as the date of occurrence. Patients were included in the analysis until an unknown response for malignancy was reported. Therefore, the rates seen here may differ from those reported in the cumulative prevalence slide which is based on only those patients with known responses for malignancy at all follow-up time points. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

FREEDOM FROM LYMPHOMA For Adult Heart Recipients (Transplants : April 1994 - June 2009)

FREEDOM FROM LYMPHOMA by Age Group For Adult Heart Recipients (Follow-ups: April 1994 - June 2010)

FREEDOM FROM OTHER MALIGNANCY For Adult Heart Recipients (Transplants : April 1994 - June 2009)

ADULT HEART TRANSPLANT RECIPIENTS: Cause of Death (Deaths: January 1992 - June 2010)
0-30 Days (N = 4,094) 31 Days – 1 Year (N = 4,028) >1 Year – 3 Years (N = 3,166) >3 Years – 5 Years (N = 2,674) >5 Years – 10 Years (N = 6,273) >10 Years – 15 Years (N =3,616) >15 Years (N =1,753) Cardiac Allograft Vasculopathy 78 (1.9%) 195 (4.8%) 458 (14.5%) 428 (16.0%) 944 (15.0%) 521 (14.4%) 232 (13.2%) Acute Rejection 256 (6.3%) 474 (11.8%) 323 (10.2%) 122 (4.6%) 116 (1.8%) 36 (1.0%) 31 (1.8%) Lymphoma 3 (0.1%) 76 (1.9%) 110 (3.5%) 110 (4.1%) 271 (4.3%) 146 (4.0%) 61 (3.5%) Malignancy, Other 106 (2.6%) 360 (11.4%) 489 (18.3%) 1,202 (19.2%) 723 (20.0%) 293 (16.7%) CMV 4 (0.1%) 45 (1.1%) 18 (0.6%) 5 (0.2%) 6 (0.1%) 1 (0.0%) 4 (0.2%) Infection, Non-CMV 539 (13.2%) 1,203 (29.9%) 392 (12.4%) 268 (10.0%) 684 (10.9%) 373 (10.3%) 260 (14.8%) Graft Failure 1,643 (40.1%) 723 (17.9%) 732 (23.1%) 544 (20.3%) 1,112 (17.7%) 582 (16.1%) 246 (14.0%) Technical 300 (7.3%) 54 (1.3%) 36 (1.1%) 27 (1.0%) 59 (0.9%) 39 (1.1%) 38 (2.2%) Other 201 (4.9%) 312 (7.7%) 289 (9.1%) 208 (7.8%) 535 (8.5%) 296 (8.2%) 157 (9.0%) Multiple Organ Failure 591 (14.4%) 460 (11.4%) 152 (4.8%) 150 (5.6%) 441 (7.0%) 289 (8.0%) 144 (8.2%) Renal Failure 24 (0.6%) 41 (1.0%) 55 (1.7%) 95 (3.6%) 371 (5.9%) 298 (8.2%) 133 (7.6%) Pulmonary 164 (4.0%) 160 (4.0%) 123 (3.9%) 126 (4.7%) 257 (4.1%) 150 (4.1%) 77 (4.4%) Cerebrovascular 288 (7.0%) 179 (4.4%) 118 (3.7%) 102 (3.8%) 275 (4.4%) 162 (4.5%) Only known causes of death are included in the tabulation. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 Percentages represent % of deaths in the respective time period

ADULT HEART TRANSPLANT RECIPIENTS: Cause of Death from Leading Causes by Time since Transplant and Era (Deaths: January June 2010) Only known causes of death are included in the tabulation. Deaths Deaths 1998 – June 2010 ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

ADULT HEART TRANSPLANT RECIPIENTS: Relative Incidence of Leading Causes of Death (Deaths: January June 2010) ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

ADULT HEART TRANSPLANT RECIPIENTS: Cumulative Incidence of Leading Causes of Death (Transplants: January June 2009) Incidence was computed using a competing-risks extension of the Kaplan-Meier method. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

ADULT HEART TRANSPLANT RECIPIENTS: Relative Incidence of Leading Causes of Death (Deaths: January June 2010) ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

ADULT HEART TRANSPLANT RECIPIENTS: Cumulative Incidence of Leading Causes of Death (Transplants: January June 2009) Incidence was computed using a competing-risks extension of the Kaplan-Meier method. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

ADULT HEART TRANSPLANTS (1/2004-6/2009) Risk Factors for 1 Year Mortality
Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT * Temporary circulatory support includes ECMO and temporary pulsatile flow devices. 2011 (N=10,271)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Borderline Significant Risk Factors for 1 Year Mortality
Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=10,271)

Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

ADULT HEART TRANSPLANTS (1/2004-6/2009) Relative Risk of 1 Year Mortality with 95% Confidence Limits Recipient Age Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=10,271)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Relative Risk of 1 Year Mortality with 95% Confidence Limits Donor Age Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=10,271)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Relative Risk of 1 Year Mortality with 95% Confidence Limits Recipient Height Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT ISHLT J Heart Lung Transplant Oct; 30 (10): * The risk associated with recipient height should be considered in conjunction with the risk associated with recipient weight and donor weight. 2011 (N=10,271)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Relative Risk of 1 Year Mortality with 95% Confidence Limits Recipient Weight Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT ISHLT J Heart Lung Transplant Oct; 30 (10): * The risk associated with recipient weight should be considered in conjunction with the risk associated with recipient height and donor weight. 2011 (N=10,271)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Relative Risk of 1 Year Mortality with 95% Confidence Limits Donor Weight Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT ISHLT J Heart Lung Transplant Oct; 30 (10): * The risk associated with donor weight should be considered in conjunction with the risk associated with recipient height and recipient weight. 2011 (N=10,271)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Relative Risk of 1 Year Mortality with 95% Confidence Limits Ischemia Time Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=10,271)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Relative Risk of 1 Year Mortality with 95% Confidence Limits Center Volume Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=10,271)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Relative Risk of 1 Year Mortality with 95% Confidence Limits Pre-Transplant Bilirubin Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=10,271)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Relative Risk of 1 Year Mortality with 95% Confidence Limits Pre-Transplant Creatinine Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=10,271)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Relative Risk of 1 Year Mortality with 95% Confidence Limits PRA Class II (%) Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=10,271)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Relative Risk of 1 Year Mortality with 95% Confidence Limits Pulmonary Capillary Wedge Pressure Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=10,271)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Relative Risk of 1 Year Mortality with 95% Confidence Limits Recipient PVR Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=10,271)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Factors Not Significant for 1 Year Mortality
Recipient Factors: Prior malignancy, hospitalized, prior pregnancy, balloon pump, diabetes, gender Donor Factors: Clinical infection, history of diabetes, gender, history of hypertension, cause of death, history of malignancy Transplant Factors: HLA mismatch, CMV mismatch, prior transplant ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=18-30 Years Risk Factors for 1 Year Mortality Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=958)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=18-30 Years Borderline Significant Risk Factors for 1 Year Mortality Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. * Temporary circulatory support includes ECMO and temporary pulsatile flow devices. There were too few temporary continuous flow devices to analyze. ISHLT ISHLT J Heart Lung Transplant Oct; 30 (10): 2011 (N=958)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=18-30 Years Risk Factors for 1 Year Mortality Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=18-30 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Recipient Age Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=958)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=18-30 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Donor Age Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=958)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=18-30 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Pre-Transplant Creatinine Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=958)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=18-30 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits PRA Class I (%) Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=958)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=18-30 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Recipient PA Systolic Pressure Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=958)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=31-60 Years Risk Factors for 1 Year Mortality Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT ISHLT J Heart Lung Transplant Oct; 30 (10): * Temporary circulatory support includes ECMO and temporary pulsatile flow devices. 2011 (N=6,583)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=31-60 Years Borderline Significant Risk Factors for 1 Year Mortality Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=6,583)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=31-60 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Recipient Age Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=6,583)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=31-60 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Donor Age Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=6,583)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=31-60 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Recipient Height Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT ISHLT J Heart Lung Transplant Oct; 30 (10): * The risk associated with recipient height should be considered in conjunction with the risk associated with recipient weight and BMI ratio. 2011 (N=6,583)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=31-60 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Recipient Weight Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT ISHLT J Heart Lung Transplant Oct; 30 (10): * The risk associated with recipient weight should be considered in conjunction with the risk associated with recipient height and BMI ratio. 2011 (N=6,583)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=31-60 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Donor BMI Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT ISHLT J Heart Lung Transplant Oct; 30 (10): * The risk associated with donor BMI should be considered in conjunction with the risk associated with BMI ratio. 2011 (N=6,583)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=31-60 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Pre-Transplant Creatinine Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=6,583)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=31-60 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Pre-Transplant Bilirubin Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=6,583)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=31-60 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Ischemia Time Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=6,583)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=31-60 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits PRA Class I (%) Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=6,583)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=31-60 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Recipient PA Diastolic Pressure Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=6,583)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=61-75 Years Risk Factors for 1 Year Mortality Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. * Temporary circulatory support includes ECMO and temporary pulsatile flow devices. There were too few temporary continuous flow devices to analyze. ISHLT ISHLT J Heart Lung Transplant Oct; 30 (10): 2011 (N=2,721)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=61-75 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Donor Age Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=2,721)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=61-75 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Recipient Height Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=2,721)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=61-75 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Ischemia Time Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=2,721)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=61-75 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Pre-Transplant Creatinine Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=2,721)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=61-75 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Pre-Transplant Bilirubin Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=2,721)

ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=61-75 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits TPG Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=2,721)

Multivariable analysis was performed using a proportional hazards model censoring all patients at 5 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. * Temporary circulatory support includes ECMO and temporary pulsatile flow devices. There were too few temporary continuous flow devices to analyze. ISHLT ISHLT J Heart Lung Transplant Oct; 30 (10): 2011 (N=10,785)

Multivariable analysis was performed using a proportional hazards model censoring all patients at 5 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=10,785)

ADULT HEART TRANSPLANTS (1/2000-6/2005) Relative Risk of 5 Year Mortality with 95% Confidence Limits Recipient Age Multivariable analysis was performed using a proportional hazards model censoring all patients at 5 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=10,785)

ADULT HEART TRANSPLANTS (1/2000-6/2005) Relative Risk of 5 Year Mortality with 95% Confidence Limits Recipient Height Multivariable analysis was performed using a proportional hazards model censoring all patients at 5 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=10,785)

ADULT HEART TRANSPLANTS (1/2000-6/2005) Relative Risk of 5 Year Mortality with 95% Confidence Limits Donor Age Multivariable analysis was performed using a proportional hazards model censoring all patients at 5 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=10,785)

ADULT HEART TRANSPLANTS (1/2000-6/2005) Relative Risk of 5 Year Mortality with 95% Confidence Limits Donor and Recipient BMI Difference Multivariable analysis was performed using a proportional hazards model censoring all patients at 5 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=10,785)

ADULT HEART TRANSPLANTS (1/2000-6/2005) Relative Risk of 5 Year Mortality with 95% Confidence Limits Recipient Pre-Transplant Bilirubin Multivariable analysis was performed using a proportional hazards model censoring all patients at 5 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=10,785)

ADULT HEART TRANSPLANTS (1/2000-6/2005) Relative Risk of 5 Year Mortality with 95% Confidence Limits TPG Multivariable analysis was performed using a proportional hazards model censoring all patients at 5 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=10,785)

ADULT HEART TRANSPLANTS (1/2000-6/2005) Relative Risk of 5 Year Mortality with 95% Confidence Limits Ischemia Time Multivariable analysis was performed using a proportional hazards model censoring all patients at 5 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=10,785)

ADULT HEART TRANSPLANTS (1/2000-6/2005) Relative Risk of 5 Year Mortality with 95% Confidence Limits Recipient Pre-Transplant Creatinine Multivariable analysis was performed using a proportional hazards model censoring all patients at 5 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=10,785)

ADULT HEART TRANSPLANTS (1/2000-6/2005) Relative Risk of 5 Year Mortality with 95% Confidence Limits Center Volume Multivariable analysis was performed using a proportional hazards model censoring all patients at 5 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=10,785)

ADULT HEART TRANSPLANTS (1/2000-6/2005) Factors Not Significant for 5 Year Mortality
Recipient Factors: Sternotomy, pulmonary embolism, IV inotropes, prior malignancy, balloon pump Donor Factors: History of cancer, clinical infection, cause of death, history of hypertension Transplant Factors: CMV mismatch, ABO match, previous transplant ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011

ADULT HEART TRANSPLANTS (1/2000-6/2005) Risk Factors for 5 Year Mortality Conditional on Survival to 1 Year Multivariable analysis was performed for all transplants surviving at least 1 year, using a proportional hazards model censoring all patients at 5 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=9,189)

ADULT HEART TRANSPLANTS (1/2000-6/2005) Risk Factors for 5 Year Mortality Conditional on Survival to 1 Year (cont’d) Multivariable analysis was performed for all transplants surviving at least 1 year, using a proportional hazards model censoring all patients at 5 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=9,189)

ADULT HEART TRANSPLANTS (1/2000-6/2005) Borderline Significant Risk Factors for 5 Year Mortality Conditional on Survival to 1 Year Multivariable analysis was performed for all transplants surviving at least 1 year, using a proportional hazards model censoring all patients at 5 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=9,189)

ADULT HEART TRANSPLANTS (1/2000-6/2005) Risk Factors for 5 Year Mortality Conditional on Survival to 1 Year Multivariable analysis was performed for all transplants surviving at least 1 year, using a proportional hazards model censoring all patients at 5 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=9,189)

ADULT HEART TRANSPLANTS (1/2000-6/2005) Relative Risk of 5 Year Mortality with 95% Confidence Limits Conditional on Survival to 1 Year Recipient Age Multivariable analysis was performed for all transplants surviving at least 1 year, using a proportional hazards model censoring all patients at 5 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=9,189)

ADULT HEART TRANSPLANTS (1/2000-6/2005) Relative Risk of 5 Year Mortality with 95% Confidence Limits Conditional on Survival to 1 Year Recipient BMI Multivariable analysis was performed for all transplants surviving at least 1 year, using a proportional hazards model censoring all patients at 5 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=9,189)

ADULT HEART TRANSPLANTS (1/2000-6/2005) Relative Risk of 5 Year Mortality with 95% Confidence Limits Conditional on Survival to 1 Year Donor Age Multivariable analysis was performed for all transplants surviving at least 1 year, using a proportional hazards model censoring all patients at 5 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=9,189)

ADULT HEART TRANSPLANTS (1/2000-6/2005) Relative Risk of 5 Year Mortality with 95% Confidence Limits Conditional on Survival to 1 Year PVR Multivariable analysis was performed for all transplants surviving at least 1 year, using a proportional hazards model censoring all patients at 5 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=9,189)

ADULT HEART TRANSPLANTS (1/2000-6/2005) Relative Risk of 5 Year Mortality with 95% Confidence Limits Conditional on Survival to 1 Year Center Volume Multivariable analysis was performed using a proportional hazards model censoring all patients at 5 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=9,189)

ADULT HEART TRANSPLANTS (1/2000-6/2005) Relative Risk of 5 Year Mortality with 95% Confidence Limits Conditional on Survival to 1 Year Pre-Transplant Recipient Serum Creatinine Multivariable analysis was performed using a proportional hazards model censoring all patients at 5 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=9,189)

ADULT HEART TRANSPLANTS (1995-6/2000) Risk Factors for 10 Year Mortality
Multivariable analysis was performed using a proportional hazards model censoring all patients at 10 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT (N=11,861) 2011

ADULT HEART TRANSPLANTS (1995-6/2000) Borderline Significant Risk Factors for 10 Year Mortality

ADULT HEART TRANSPLANTS (1995-6/2000) Risk Factors for 10 Year Mortality

ADULT HEART TRANSPLANTS (1995-6/2000) Relative Risk of 10 Year Mortality with 95% Confidence Limits Recipient Age Multivariable analysis was performed using a proportional hazards model censoring all patients at 10 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT (N=11,861) 2011

ADULT HEART TRANSPLANTS (1995-6/2000) Relative Risk of 10 Year Mortality with 95% Confidence Limits Donor Age Multivariable analysis was performed using a proportional hazards model censoring all patients at 10 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT (N=11,861) 2011

ADULT HEART TRANSPLANTS (1995-6/2000) Relative Risk of 10 Year Mortality with 95% Confidence Limits Pre-Transplant Recipient Weight Multivariable analysis was performed using a proportional hazards model censoring all patients at 10 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT (N=11,861) 2011

ADULT HEART TRANSPLANTS (1995-6/2000) Relative Risk of 10 Year Mortality with 95% Confidence Limits Pre-Transplant Recipient Height Multivariable analysis was performed using a proportional hazards model censoring all patients at 10 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT (N=11,861) 2011

ADULT HEART TRANSPLANTS (1995-6/2000) Relative Risk of 10 Year Mortality with 95% Confidence Limits Ischemia Time Multivariable analysis was performed using a proportional hazards model censoring all patients at 10 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT (N=11,861) 2011

ADULT HEART TRANSPLANTS (1995-6/2000) Relative Risk of 10 Year Mortality with 95% Confidence Limits Recipient Pre-Transplant Creatinine Multivariable analysis was performed using a proportional hazards model censoring all patients at 10 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT (N=11,861) 2011

ADULT HEART TRANSPLANTS (1995-6/2000) Relative Risk of 10 Year Mortality with 95% Confidence Limits Recipient Pre-Transplant Bilirubin Multivariable analysis was performed using a proportional hazards model censoring all patients at 10 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT (N=11,861) 2011

ADULT HEART TRANSPLANTS (1995-6/2000) Relative Risk of 10 Year Mortality with 95% Confidence Limits Center Volume Multivariable analysis was performed using a proportional hazards model censoring all patients at 10 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT (N=11,861) 2011

ADULT HEART TRANSPLANTS Risk Factors for 15 Year Mortality

ADULT HEART TRANSPLANTS (1/1990-6/1995) Relative Risk of 15 Year Mortality with 95% Confidence Limits Recipient Age Multivariable analysis was performed using a proportional hazards model censoring all patients at 15 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT (N=10,342) 2011

ADULT HEART TRANSPLANTS (1/1990-6/1995) Relative Risk of 15 Year Mortality with 95% Confidence Limits Donor Age Multivariable analysis was performed using a proportional hazards model censoring all patients at 15 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT (N=10,342) 2011

ADULT HEART TRANSPLANTS (1/1990-6/1995) Relative Risk of 15 Year Mortality with 95% Confidence Limits Recipient Height Multivariable analysis was performed using a proportional hazards model censoring all patients at 15 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT (N=10,342) 2011

ADULT HEART TRANSPLANTS (1/1990-6/1995) Relative Risk of 15 Year Mortality with 95% Confidence Limits Recipient Weight Multivariable analysis was performed using a proportional hazards model censoring all patients at 15 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT (N=10,342) 2011

ADULT HEART TRANSPLANTS (1/1990-6/1995) Relative Risk of 15 Year Mortality with 95% Confidence Limits Recipient Pre-Transplant Creatinine Multivariable analysis was performed using a proportional hazards model censoring all patients at 15 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT (N=10,342) 2011

ADULT HEART TRANSPLANTS (1/1990-6/1995) Relative Risk of 15 Year Mortality with 95% Confidence Limits Ischemia Time Multivariable analysis was performed using a proportional hazards model censoring all patients at 15 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT (N=10,342) 2011

ADULT HEART TRANSPLANTS (1/1990-6/1995) Relative Risk of 15 Year Mortality with 95% Confidence Limits Recipient Pre-Transplant PRA Multivariable analysis was performed using a proportional hazards model censoring all patients at 15 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT (N=10,342) 2011

ADULT HEART TRANSPLANTS Risk Factors for 20 Year Mortality

ADULT HEART TRANSPLANTS (1/1985-6/1990) Relative Risk of 20 Year Mortality with 95% Confidence Limits Recipient Age Multivariable analysis was performed using a proportional hazards model censoring all patients at 20 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT (N=13,578) 2011

ADULT HEART TRANSPLANTS (1/1985-6/1990) Relative Risk of 20 Year Mortality with 95% Confidence Limits Donor Age Multivariable analysis was performed using a proportional hazards model censoring all patients at 20 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT (N=13,578) 2011

ADULT HEART TRANSPLANTS (1/1985-6/1990) Relative Risk of 20 Year Mortality with 95% Confidence Limits Ischemia Time Multivariable analysis was performed using a proportional hazards model censoring all patients at 20 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT (N=10,342) 2011

ADULT HEART TRANSPLANTS (1/1985-6/1990) Relative Risk of 20 Year Mortality with 95% Confidence Limits Center Volume Multivariable analysis was performed using a proportional hazards model censoring all patients at 20 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT (N=10,342) 2011

ADULT HEART TRANSPLANTS (1/2003-6/2009) Risk Factors for Developing Renal Dysfunction within 1 Year Limited to Recipients without Severe Renal Dysfunction* Pre-Transplant Conditional on Survival to Transplant Discharge Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT *Severe renal dysfunction = creatinine > 2.5 mg/dl or dialysis 2011 (N=9,916)

ADULT HEART TRANSPLANTS (1/2003-6/2009) Borderline Significant Risk Factors for Developing Renal Dysfunction within 1 Year Limited to Recipients without Severe Renal Dysfunction* Pre-Transplant Conditional on Survival to Transplant Discharge Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT *Severe renal dysfunction = creatinine > 2.5 mg/dl or dialysis 2011 (N=9,916)

ADULT HEART TRANSPLANTS (1/2003-6/2009) Risk Factors for Developing Renal Dysfunction within 1 Year Limited to Recipients without Severe Renal Dysfunction Pre-Transplant Conditional on Survival to Transplant Discharge Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. *Severe renal dysfunction = creatinine > 2.5 mg/dl or dialysis ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=9,916)

ADULT HEART TRANSPLANTS (1/2003-6/2009) Risk Factors for Developing Renal Dysfunction within 1 Year Limited to Recipients without Severe Renal Dysfunction* Pre-Transplant Conditional on Survival to Transplant Discharge Recipient Age Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. *Severe renal dysfunction = creatinine > 2.5 mg/dl or dialysis ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=9,916)

ADULT HEART TRANSPLANTS (1/2003-6/2009) Risk Factors for Developing Renal Dysfunction within 1 Year Limited to Recipients without Severe Renal Dysfunction* Pre-Transplant Conditional on Survival to Transplant Discharge Recipient Pre-Transplant Creatinine Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. *Severe renal dysfunction = creatinine > 2.5 mg/dl or dialysis ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=9,916)

ADULT HEART TRANSPLANTS (1/2003-6/2009) Risk Factors for Developing Renal Dysfunction within 1 Year Limited to Recipients without Severe Renal Dysfunction* Pre-Transplant Conditional on Survival to Transplant Discharge Recipient Pre-Transplant Weight Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. *Severe renal dysfunction = creatinine > 2.5 mg/dl or dialysis ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=9,916)

ADULT HEART TRANSPLANTS (1/2003-6/2009) Risk Factors for Developing Renal Dysfunction within 1 Year Limited to Recipients without Severe Renal Dysfunction* Pre-Transplant Conditional on Survival to Transplant Discharge Recipient PA Systolic Pressure Multivariable analysis was performed using a proportional hazards model censoring all patients at 1 year. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT *Severe renal dysfunction = creatinine > 2.5 mg/dl or dialysis 2011 (N=9,916)

ADULT HEART TRANSPLANTS (1/1998-6/2002) Risk Factors for Developing Cardiac Allograft Vasculopathy within 8 Years Conditional on Survival to Transplant Discharge Multivariable analysis was performed using a proportional hazards model. Follow-up was censored at 8 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=6,264)

ADULT HEART TRANSPLANTS (1/1998-6/2002) Borderline Significant Risk Factors for Developing Cardiac Allograft Vasculopathy within 8 Years Conditional on Survival to Transplant Discharge Multivariable analysis was performed using a proportional hazards model. Follow-up was censored at 8 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=6,264)

Conditional on Survival to Transplant Discharge
ADULT HEART TRANSPLANTS (1/1998-6/2002) Risk Factors for Developing Cardiac Allograft Vasculopathy within 8 Years Conditional on Survival to Transplant Discharge Multivariable analysis was performed using a proportional hazards model. Follow-up was censored at 8 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=6,264)

ADULT HEART TRANSPLANTS (1/1998-6/2002) Relative Risk of Developing Cardiac Allograft Vasculopathy within 8 Years Conditional on Survival to Transplant Discharge Recipient Age Multivariable analysis was performed using a proportional hazards model. Follow-up was censored at 8 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=6,264)

ADULT HEART TRANSPLANTS (1/1998-6/2002) Relative Risk of Developing Cardiac Allograft Vasculopathy within 8 Years Conditional on Survival to Transplant Discharge Donor BSA Multivariable analysis was performed using a proportional hazards model. Follow-up was censored at 8 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=6,264)

ADULT HEART TRANSPLANTS (1/1998-6/2002) Relative Risk of Developing Cardiac Allograft Vasculopathy within 8 Years Conditional on Survival to Transplant Discharge Donor Age Multivariable analysis was performed using a proportional hazards model. Follow-up was censored at 8 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=6,264)

ADULT HEART TRANSPLANTS (1/1998-6/2002) Relative Risk of Developing Cardiac Allograft Vasculopathy within 8 Years Conditional on Survival to Transplant Discharge Center Volume Multivariable analysis was performed using a proportional hazards model. Follow-up was censored at 8 years. Continuous factors were fit using a restricted cubic spline. Analyses were limited to transplants having essentially complete information regarding risk factors. ISHLT J Heart Lung Transplant Oct; 30 (10): ISHLT 2011 (N=6,264)

HEART TRANSPLANTATION

Similar presentations

Presentation on theme: "HEART TRANSPLANTATION"— Presentation transcript:

Similar presentations

About project

Feedback

Log in

Auth with social network:

HEART TRANSPLANTATION

Similar presentations

Presentation on theme: "HEART TRANSPLANTATION"— Presentation transcript:

Similar presentations

About project

Feedback